News archive
341 results
Fimea to investigate the conformity of software-based medical devices
New application to improve management of clinical trials
Marketing authorisation for Litalgin products cancelled for safety reasons in summer 2024 – these products should no longer be used
2024 annual report on the supervision of the quality and safety of substances of human origin has been published
Fimea’s sustainability report for 2024 has been published
Cross-border ePrescription is perceived to improve access to medicines, tools are needed for patient counselling to improve medication safety
Mesalazine-containing enteric-coated tablets are in short supply
Registration open for Fimea’s NIS2 entity list
Stakeholders show interest in medicines data repository
New designer drugs to be subject to control
Cybersecurity Act enters into force - new regulation for operators
Fimea organises a Horizon Scanning event for pharmaceutical companies 16th of May
Development of the national medicines data repository has been launched
The Nordic Council of Ministers’ Blood, Tissue and Cell Working Group to meet in Helsinki
Johanna Seppänen appointed Director of Development and Information Services at Fimea
Fimea’s final accounts and annual report for 2024 have been published
Extension to the scope of the Finnish notified body
The process of developing the National High-Risk Medicines Classification is described in an international article
European Medicines Agency’s monitoring platform for shortages is now in use – training available for marketing authorisation holders
Language versions of the patient engagement checklist in research published
Showing 1 - 20 / 341
